Today we are able to announce positive topline data from our Phase I/IIa clinical trial of NMD670 in patients with Myasthenia Gravis

All primary endpoints and all secondary endpoints were met. This important data provides the first clinical proof of concept of NMD Pharma’s muscle electrophysiology platform.